Extrapyramidal system

Singapore's Largest Brick-and-Mortar Nutrition Brand LAC Launches Nutrition for Life Campaign, Advocates Holistic Wellness with Minimal Effort

Retrieved on: 
Tuesday, November 21, 2023
Liver, Extrapyramidal system, Dermatitis, Work, Census of agriculture, Risk, Immune system, Woman, Ginkgo, Health, Hawthorn, Life, Nutrient, Lotus, Blood, Brain, SUPER, Medicine, DHA, Digestion, COVID, Thiamine, EPA, Radical, Infection, Oxidative stress, Liver disease, Mother, Forgetting, Memory, Immunity, Fatigue, Skin, Vitamin B3, Dietary supplement

This is the first LAC-branded event since the health and wellness brand opened 54 physical stores in Singapore, further increasing its footprint in the region.

Key Points: 
  • This is the first LAC-branded event since the health and wellness brand opened 54 physical stores in Singapore, further increasing its footprint in the region.
  • "The Nutrition for Life campaign embodies LAC's commitment to inspire Singaporeans to lead healthier and more fulfilling lifestyles.
  • Our range of proprietary blends is a step towards helping people seamlessly incorporate supplements into their daily lives.
  • LAC MASQUELIER's(R) French Pine Bark Extract: SUPER ANTIOXIDANT, Perfect for Immunity Boosting
    Start the day with Masquelier's French Pine Bark.

Olathe Organ Donor to be Honored in 2024 Rose Parade® on Jan. 1

Retrieved on: 
Thursday, December 28, 2023
Liver, Extrapyramidal system, Music, Family, Universal language, Dream, Interview, Butterfly Dance, ABC, Seed, Portrait, APR, Dandy–Walker malformation, Parent, Language, Eye, Univision, NBC, The Butterfly Dance, CST, Love, The Dance of Life, Fruit, Community engagement, Dance, Television, Flower, Entertainment

Kansas City, KS., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Midwest Transplant Network will honor 14-year-old organ donor Jayme Sue Louque of Olathe, Kansas, in the 2024 Rose Parade ®.

Key Points: 
  • Kansas City, KS., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Midwest Transplant Network will honor 14-year-old organ donor Jayme Sue Louque of Olathe, Kansas, in the 2024 Rose Parade ®.
  • The OneLegacy Donate Life Rose Parade® float will feature a floragraph portrait of Jayme Sue, among other donor hero floragraphs.
  • The 135th Rose Parade® will air on television Monday, Jan. 1 at 10 a.m. CST on ABC, NBC and Univision.
  • For more than 20 years, the OneLegacy Donate Life Rose Parade® float has inspired people across the country with the powerful message of organ, eye and tissue donation.

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Retrieved on: 
Thursday, December 21, 2023
Bone marrow, Plasma, Disease, TSS, Cancer, Ruxolitinib, Extrapyramidal system, Fibrosis, LOXL2, Patient, Safety, Nature, Jaki, Pharmaceutical industry

Six out of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, an improvement suggesting that GB2064 could impact the progression of the disease and be disease-modifying.

Key Points: 
  • Six out of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, an improvement suggesting that GB2064 could impact the progression of the disease and be disease-modifying.
  • Fibrosis is a key disease mechanism of myelofibrosis that destroys bone marrow function.
  • Bone marrow biopsies taken during the study showed that GB2064 penetrated the bone marrow and could exert its anti-fibrotic effect directly in the disease compartment.
  • All six patients who experienced a > 1-grade reduction in bone marrow fibrosis score also showed stable hematological parameters, including hemoglobin, white blood cell count and platelets.

EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis

Retrieved on: 
Tuesday, December 5, 2023
Patient, Hospital, Dysphagia, Heartburn, Eosinophilic esophagitis, Drinking, Barrett's esophagus, Extrapyramidal system, Conditional sentence, Esophagus, Fungal infection, Eosinophil, Safety, Vomiting, Esophageal cancer, Candidiasis

The ACESO study is a randomized, placebo-controlled, double-blind Phase II study to evaluate the efficacy, tolerability and safety of ESO-101 in patients with active eosinophilic esophagitis (EoE).

Key Points: 
  • The ACESO study is a randomized, placebo-controlled, double-blind Phase II study to evaluate the efficacy, tolerability and safety of ESO-101 in patients with active eosinophilic esophagitis (EoE).
  • "The ACESO study represents an important milestone in the development of our unique application platform for the treatment of esophageal diseases.
  • Following the successful results of this Phase II study, we now plan to initiate a Phase III program in eosinophilic esophagitis,” said Isabelle Racamier, CEO of EsoCap.
  • The detailed results from the ACESO study, including secondary endpoint data, will be submitted for presentation at a future scientific conference.

LifeVantage® Study Reveals Synergistic Effects of Protandim® Nrf2 Synergizer® and TrueScience® Liquid Collagen

Retrieved on: 
Wednesday, November 29, 2023
Spleen, RNA, Extrapyramidal system, Research and development, Liver, Science, Protein, Extracellular matrix, Immune system, Elastin, Fibroblast, Protandim, Lung, Blood, Health, Collagen, Brain, Cryotherapy, Gene, Kidney, Cell, Laminin, Skin, Vaccine

The study results showed that when combined, the products work together to help cells accurately respond to stress levels and recover more quickly, supporting the body’s immune function.

Key Points: 
  • The study results showed that when combined, the products work together to help cells accurately respond to stress levels and recover more quickly, supporting the body’s immune function.
  • “When cells are stressed they send out signals asking for help from the immune system,” explained Lisa Barnes, Vice President of Research & Development.
  • To understand why, Barnes and team devised a study in three parts: a dose-finding study, a gene expression study to verify dose timing and concentration, and a global gene expression study using RNA sequencing.
  • Around 21% (2,786 genes) were significantly up, or downregulated either by Protandim Nrf2 Synergizer®, TrueScience® Liquid Collagen, or a combination of the two.

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Retrieved on: 
Tuesday, November 28, 2023
HIV-1, Risk, Heartburn, MOA, Enzyme inhibitor, Potassium, FDA, Magnesium, Nausea, PPI, Inflammation, Prescription, Esophagus, Bone fracture, Skin, Chills, Extrapyramidal system, Fever, Vitamin, Breast milk, Infection, Diarrhea, Helicobacter pylori, Indigestion, Bleeding, Disease, Muscle weakness, Tongue, Calcium, Acid, University, Human, Pharmacy, Clostridioides, Vonoprazan, Urine, Hip, B-12, Food, Polyp, Esophagitis, GERD, Chronic pain, Blood, Dizziness, Blister, Gastroesophageal reflux disease, Tablet, Vitamin B12, Scar, Patient, Wrist, Medicine, Seizure, HIV, Stomach, Lymph, Allergy, Clostridioides difficile, Rash, Weakness, Urinary tract infection, Hypoesthesia, Week, Myalgia, Spine, Spasm, Kidney, Face, Rilpivirine, Lansoprazole, Pharmaceutical industry

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.

Key Points: 
  • “We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.
  • “Erosive GERD is a highly prevalent condition affecting over 20 million people in the U.S.,3,4 many of whom experience troubling symptoms, including painful heartburn.
  • Phathom is offering programs for eligible patients who face coverage or affordability issues, including co-pay assistance for patients with commercial insurance.
  • for up to 6 months to maintain healing of Erosive Acid Reflux and for relief of heartburn related to Erosive Acid Reflux.

CPSC Warns Consumers to Immediately Stop Using Yntezhya US Shop High-Powered Magnetic Ball Sets Due to Ingestion Hazard; Failure to Meet Federal Safety Regulation for Toy Magnet Sets; Sold Exclusively at Amazon.com

Retrieved on: 
Thursday, December 21, 2023
Extrapyramidal system, Risk, Death, Infection, CPSC, Tin, Human, Magnet, Sepsis, Amazon (company)

CPSC is aware of seven deaths involving the ingestion of hazardous magnets, including two outside of the United States.

Key Points: 
  • CPSC is aware of seven deaths involving the ingestion of hazardous magnets, including two outside of the United States.
  • CPSC issued a Notice of Violation to the seller, Yntezhya US Shop, of China, but the firm has not agreed to recall these magnetic ball sets or offer a remedy to consumers.
  • The sets were sold in a set of multi-colored magnetic balls in the form of a cube.
  • CPSC urges consumers to stop using the magnetic ball sets immediately, take them away from children, and dispose of them.

CPSC Warns Consumers to Immediately Stop Using Doraemon High-Powered Magnetic Ball Sets Due to Ingestion Hazard; Failure to Meet Federal Safety Regulation for Toy Magnet Sets; Sold Exclusively at Amazon.com

Retrieved on: 
Thursday, December 21, 2023
Extrapyramidal system, Risk, Death, Infection, CPSC, Tin, Human, Magnet, Sepsis, Amazon (company)

CPSC is aware of seven deaths involving the ingestion of hazardous magnets, including two outside of the United States.

Key Points: 
  • CPSC is aware of seven deaths involving the ingestion of hazardous magnets, including two outside of the United States.
  • CPSC issued a Notice of Violation to the seller, Doraemon, of China, but the firm has not agreed to recall these magnetic ball sets or offer a remedy to consumers.
  • The sets were sold in a set of multi-colored magnetic balls in the form of a cube.
  • CPSC urges consumers to stop using the Magnetic Ball Sets immediately, take them away from children, and dispose of them.

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Retrieved on: 
Tuesday, November 14, 2023
Vomiting, Absorption, Evoke, Disease, Gastroparesis, Tablet, Patient, FDA, Metoclopramide, Extrapyramidal system, Patent, Diabetes, Pharmaceutical industry

SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.

Key Points: 
  • SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No.
  • 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI.
  • This new patent, issued on November 14, 2023, provides Evoke with additional intellectual property protections with claims to metoclopramide being delivered intranasally, amongst others.
  • GIMOTI is the only outpatient, non-oral drug labeled for the treatment of acute and recurrent diabetic gastroparesis.

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
EASD, Negotiation, SAN, Capital structure, Extrapyramidal system, IND$FILE, Therapy, Toxicity, JAK, IND, File, Liver, Comparison, RSU, Patient, Data analysis, FDA, Animal, Ulcerative colitis, GI, Aviation, Patent, Pharmaceutical industry, Clothing, Cryptocurrency, Diabetes

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery of large molecules
    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
  • “The third quarter was also marked by accelerating development of our BioJet™ platform.
  • We progressed our three existing pharma collaborations during the quarter and are actively negotiating with a potential fourth pharma collaborator.
  • Biora filed an IND application with the FDA for BT-600 in September 2023.